Connect your AI

Inhibrx Biosciences, Inc. INBX Price / book

Price / book at other companies

PfizerPFE

1.8×+0.2×

Rogers CorporationROG

1.6×+0.6×

Merck & Co.MRK

6.5×+1.8×

Gilead SciencesGILD

7.4×+0.1×

Nuvation BioNUVB

4.7×+3.2×

ArriVent BioPharma, Inc.AVBP

3.1×0.0×

Other financials

Income statement

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Calculated from Inhibrx Biosciences, Inc.’s reported figures.

market cap/total stockholders equity=143.7×

Based on the most recent quarter.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Inhibrx Biosciences, Inc.'s price / book?: Inhibrx Biosciences, Inc. (INBX) reported price / book of 143.7× in Q4 2025.
How has Inhibrx Biosciences, Inc.'s price / book changed year-over-year?: Inhibrx Biosciences, Inc.'s price / book increased by 8513.7% year-over-year, from 1.7× to 143.7×.
What is the long-term trend for Inhibrx Biosciences, Inc.'s price / book?: Over 3 years (2022 to 2025), Inhibrx Biosciences, Inc.'s price / book has grown at a 186.0% compound annual growth rate (CAGR), from 6.1× to 143.7×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.